<DOC>
	<DOCNO>NCT02095171</DOCNO>
	<brief_summary>This single ascend dose study determine safety , tolerability , pharmacokinetics immunogenicity PRX002 approximately 40 healthy subject .</brief_summary>
	<brief_title>Single Ascending Dose Study PRX002 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Healthy subject Body mass index ( BMI ) 1832 kg/m2 minimum weight 46 kg Female subject must surgically sterile postmenopausal childbearing potential must use contraception Male subject partner childbearing potential must use contraception Positive test drug abuse Past current history alcohol abuse Positive hepatitis B , hepatitis C HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>